Antibody response to pneumococcal capsular polysaccharide vaccine in African children.
Antibody titers to six pneumococcal polysaccharides were measured by enzyme-linked immunosorbent assay in Gambian children before and 1 month after vaccination with a 23-valent pneumococcal capsular polysaccharide vaccine at the ages of 2, 4, 6 or 9 months or at 5 to 10 years of age. IgG responses to type 1, 3 and 5 polysaccharides were seen in children in all age groups. Responses to type 19F and 23F polysaccharides were seen only in the oldest children. Few children of any age responded to immunization with type 6A pneumococcal polysaccharide. The immune response of Gambian infants to immunization with six components of a polyvalent pneumococcal polysaccharide vaccine was comparable with that described previously in Finnish infants and would be unlikely to provide substantial protection against invasive pneumococcal disease.
Temple
K
K
Medical Research Council Laboratories, Fajara, Banjul, The Gambia.
Greenwood
B
B
Inskip
H
H
Hall
A
A
Koskela
M
M
Leinonen
M
M
D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001428:Bacterial Vaccines / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005714:Gambia; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis*; D007223:Infant; D022242:Pneumococcal Vaccines; D013296:Streptococcus pneumoniae / Q000276:immunology*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007136:Immunoglobulins; D022242:Pneumococcal Vaccines